PneumRx, Inc.
14
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
35.7%
5 terminated/withdrawn out of 14 trials
54.5%
-32.0% vs industry average
7%
1 trials in Phase 3/4
67%
4 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Study of PneumRx Endobronchial Coil System in Treatment of Subjects With Severe Emphysema
Role: collaborator
Evaluation of the PneumRx Lung Volume Reduction Coil to Treat Emphysema
Role: collaborator
Feasibility Study of PneumRx's Lung Volume Reduction Coil (LVRC)
Role: collaborator
Randomized Comparison of the RePneu Lung Volume Reduction Coil (LVRC) to Standard of Care for the Treatment of Emphysema (RESET Study)
Role: collaborator
LVRC IDE Crossover Study (Crossover From IDE Trial CLN0009)
Role: collaborator
Changes in Lung Physiology and Cardiac Performance in Patients With Emphysema Post Bilateral RePneu Coil Treatment
Role: collaborator
Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study
Role: collaborator
Chronic Obstructive Pulmonary Disease (COPD) Co-Pilot AIR Substudy of CLN0014
Role: collaborator
Post Market Observational, Prospective, Multi-center Study
Role: collaborator
Evaluation of Physiologic Parameters to Study the Mechanism of Action of the Lung Volume Reduction Coil in Subjects With Homogeneous Emphysema
Role: collaborator
Improvement of Sleep Quality by RePneu® Coils in Advanced Pulmonary Emphysema
Role: collaborator
Evaluation of COPD Co-Pilot
Role: collaborator
Evaluation of COPD Co-Pilot
Role: collaborator
Lung Volume Reduction Coil Treatment in Emphysema.
Role: collaborator
All 14 trials loaded